The effect of tesofensine on appetite sensations.

Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A

Obesity (Silver Spring, Md.)30 Jun 2011Cited by 32 (Europe PMC)

PMID21720440DOI10.1038/oby.2011.197PepBankPUB-21720440

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In trial participants, tesofensine increased composite satiety scores dose-dependently at week 12.
In plain wordsIn trial participants, tesofensine increased combined satiety scores dose-dependently at week 12.
Peptide
Tesofensine
Outcome
IncreaseComposite satiety score at week 12
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.25, 0.5 or 1.0 mg · 12 weeksAs given in this study (human).
Source sentences
Summary
In Part 1 TE induced a dose-dependent increase in CSS at week 12 that correlated with weight loss during the 24 weeks (r = 0.36, P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In Part 1, participants (n = 158) were assigned to 0.25, 0.5 or 1.0 mg TE, or placebo.
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
Report a problemFND-2172044001
02HumanRandomized controlled trialOther
In trial participants, the tesofensine-associated satiety increase at week 12 correlated with weight loss over 24 weeks.
In plain wordsIn trial participants, greater tesofensine-associated satiety increases were linked to greater weight loss.
Peptide
Tesofensine
Outcome
IncreaseSatiety and weight loss correlation
Study
n: not reported in source
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated
Measurements
Correlation coefficient
0.36 r
satiety increase and weight loss
P value
< 0.0001
correlation
Source sentences
Summary
In Part 1 TE induced a dose-dependent increase in CSS at week 12 that correlated with weight loss during the 24 weeks (r = 0.36, P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
Report a problemFND-2172044002
03HumanRandomized controlled trialEfficacy outcome
In trial participants receiving tesofensine, composite satiety scores rose initially and diminished as weight loss progressed.
In plain wordsIn trial participants receiving tesofensine, satiety scores rose initially and then declined as weight loss progressed.
Peptide
Tesofensine
Outcome
MixedComposite satiety score over time
Study
n: not reported in source
Comparator
Baseline and week 12
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg · 24 weeksAs given in this study (human).
Measurements
CSS
52 mm
baseline, 1.0 mg
CSS
64 mm
week 12, 1.0 mg
CSS
55 mm
week 24, 1.0 mg
Source sentences
Summary
However, CSS diminished over time as weight loss progressed (e.g., for 1.0 mg; 52 ± 17 mm; 64 ± 13 mm; 55 ± 13 mm at baseline, week 12 and week 24, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
Report a problemFND-2172044003
04HumanNon-randomized trialEfficacy outcome
In returning trial participants, tesofensine reintroduction increased composite satiety scores regardless of initial treatment or weight loss.
In plain wordsIn returning trial participants, tesofensine reintroduction increased combined satiety scores regardless of initial treatment or weight loss.
Peptide
Tesofensine
Outcome
IncreaseSatiety after reintroduction
Study
n: not reported in source
Comparator
After drug withdrawal
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.5 or 1.0 mg · 24 weeksAs given in this study (human).
Measurements
CSS
56 mm
week 60 after reintroduction
Source sentences
Summary
The reintroduction of TE in Part 2 increased CSS again (56 ± 17 mm at week 60), regardless of initial treatment/weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
Completers of Part 1 were invited to participate in Part 2 (n = 113), during which they all received 0.5 or 1.0 mg TE.
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
Report a problemFND-2172044006

Studies that did not test the peptide alone2

In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tesofensine.

05HumanNot a test of Tesofensine aloneRandomized controlled trialEfficacy outcome
In the whole trial sample, satiety scores returned to baseline after drug withdrawal despite reduced body weight.
In plain wordsIn the whole trial sample, satiety scores returned to baseline after drug withdrawal despite reduced body weight.
Peptide
Tesofensine
Outcome
No significant changeComposite satiety score after withdrawal
Study
n: not reported in source
Comparator
Baseline
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
CSS
50 mm
whole sample after withdrawal
Source sentences
Summary
After drug withdrawal CSS returned to baseline values (50 ± 17 mm, in the whole sample.), despite the participants' reduced-weight state (-7.2 ± 6.7 kg, P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.
Report a problemFND-2172044004
06HumanNot a test of Tesofensine aloneRandomized controlled trialEfficacy outcome
In the whole trial sample, participants were still in a reduced-weight state after drug withdrawal.
In plain wordsIn the whole trial sample, participants were still in a reduced-weight state after drug withdrawal.
Peptide
Tesofensine
Outcome
DecreaseWeight after withdrawal
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−7.2 kg
whole sample after withdrawal
Source sentences
Summary
After drug withdrawal CSS returned to baseline values (50 ± 17 mm, in the whole sample.), despite the participants' reduced-weight state (-7.2 ± 6.7 kg, P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
In Part 1, participants (n = 158) were assigned to 0.25, 0.5 or 1.0 mg TE, or placebo.
Summary · context
Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design.
In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.
Report a problemFND-2172044005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT00481104

Evaluation of Long Term Safety of Tesofensine in Patients With Obesity

NeuroSearch A/Sn = 140May 2007 to Nov 2008

Obesity

Trial page ClinicalTrials.govUpdated 4 Jul 2011

CompletedPhase 2NCT00394667

Effect of Tesofensine on Weight Reduction in Patients With Obesity.

NeuroSearch A/Sn = 200Sept 2006 to Sept 2007

Obesity

Trial page ClinicalTrials.govUpdated 22 Apr 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.